{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:54:35Z","timestamp":1786992875875,"version":"build-2736575974"},"reference-count":40,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T00:00:00Z","timestamp":1498262400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"crossref","award":["103DHA0100371"],"award-info":[{"award-number":["103DHA0100371"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"crossref","award":["105DHA0100478"],"award-info":[{"award-number":["105DHA0100478"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Microbiology, Immunology and Infection"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.jmii.2017.04.001","type":"journal-article","created":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T23:47:53Z","timestamp":1498693673000},"page":"784-793","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy of isoniazid salvage therapy for latent tuberculosis infection in patients with immune-mediated inflammatory disorders \u2013 A retrospective cohort study in Taiwan"],"prefix":"10.1016","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6685-8259","authenticated-orcid":false,"given":"Shiang-Fen","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Han","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Der","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Youh","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Phone","family":"Fung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Juin","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmii.2017.04.001_bib1","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.coph.2004.05.003","article-title":"New approaches to therapeutic immunomodulation for immune-mediated inflammatory disorders","volume":"4","author":"Taylor","year":"2004","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.jmii.2017.04.001_bib2","first-page":"S664","article-title":"Immune-mediated inflammatory disorders (I.M.I.D.s): the economic and clinical costs","volume":"8","author":"Williams","year":"2002","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.jmii.2017.04.001_bib3","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.mcna.2009.08.003","article-title":"Evaluation and management of psoriasis: an internist's guide","volume":"93","author":"Levine","year":"2009","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.jmii.2017.04.001_bib4","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/annrheumdis-2012-203158","article-title":"EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis","volume":"72","author":"Colebatch","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jmii.2017.04.001_bib5","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/rheumatology\/ket187","article-title":"The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics","volume":"52","author":"Coates","year":"2013","journal-title":"Rheumatol Oxf"},{"key":"10.1016\/j.jmii.2017.04.001_bib6","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1093\/rheumatology\/kes026","article-title":"Update of the literature review on treatment with biologics as a basis for the first update of the ASAS\/EULAR management recommendations of ankylosing spondylitis","volume":"51","author":"Baraliakos","year":"2012","journal-title":"Rheumatol Oxf"},{"key":"10.1016\/j.jmii.2017.04.001_bib7","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jmii.2013.03.005","article-title":"Risk of tuberculosis infection in anti-TNF-alpha biological therapy: from bench to bedside","volume":"47","author":"Xie","year":"2014","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jmii.2017.04.001_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2249.2010.04146.x","article-title":"How tumour necrosis factor blockers interfere with tuberculosis immunity","volume":"161","author":"Harris","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jmii.2017.04.001_bib9","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/rheumatology\/keu172","article-title":"Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies","volume":"53","author":"Souto","year":"2014","journal-title":"Rheumatol Oxf"},{"key":"10.1016\/j.jmii.2017.04.001_bib10","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s10067-015-3099-3","article-title":"Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United Kingdom","volume":"34","author":"Nisar","year":"2015","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jmii.2017.04.001_bib11","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1136\/annrheumdis-2011-200489","article-title":"Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNFalpha inhibitors: the utility of IFNgamma assay","volume":"71","author":"Chen","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jmii.2017.04.001_bib12","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1086\/424460","article-title":"Tuberculosis cases associated with infliximab and etanercept","volume":"39","author":"Winthrop","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2017.04.001_bib13","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2017.04.001_bib14","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3899\/jrheum.140100","article-title":"Diagnostic accuracy of chest radiography for the diagnosis of tuberculosis (TB) and its role in the detection of latent TB infection: a systematic review","volume":"91","author":"Piccazzo","year":"2014","journal-title":"J Rheumatol Suppl"},{"issue":"3","key":"10.1016\/j.jmii.2017.04.001_bib15","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1136\/thoraxjnl-2015-207686","article-title":"The effect of diabetes control status on treatment response in pulmonary tuberculosis: a prospective study","volume":"72","author":"Yoon","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.jmii.2017.04.001_bib16","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s10120-011-0037-1","article-title":"Increased risk of tuberculosis after gastrectomy and chemotherapy in gastric cancer: a 7-year cohort study","volume":"14","author":"Huang","year":"2011","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.jmii.2017.04.001_bib17","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0962-8479(05)80035-8","article-title":"Tuberculosis in the autopsy material: analysis of 1500 autopsies performed between 1972 and 1991 in the Institute of Tuberculosis and Chest diseases, Warsaw, Poland","volume":"76","author":"Rowinska-Zakrzewska","year":"1995","journal-title":"Tuber Lung Dis"},{"key":"10.1016\/j.jmii.2017.04.001_bib18","first-page":"231","article-title":"Undiagnosed active tuberculosis in a medicolegal autopsy material","volume":"58","author":"Juul","year":"1977","journal-title":"Scand J Respir Dis"},{"key":"10.1016\/j.jmii.2017.04.001_bib19","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.autrev.2015.01.011","article-title":"Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice","volume":"14","author":"Cantini","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jmii.2017.04.001_bib20","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/1756-185X.12530","article-title":"Risk of tuberculosis in patients treated with anti-tumor necrosis factor therapy: a nationwide study in South Korea, a country with an intermediate tuberculosis burden","volume":"18","author":"Jung","year":"2015","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.jmii.2017.04.001_bib21","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.tube.2015.07.002","article-title":"Interferon gamma release assays for monitoring the response to treatment for tuberculosis: A systematic review","volume":"95","author":"Clifford","year":"2015","journal-title":"Tuberc (Edinb)"},{"key":"10.1016\/j.jmii.2017.04.001_bib22","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.5588\/ijtld.15.0057","article-title":"Previous history of tuberculosis is associated with rheumatoid arthritis","volume":"19","author":"Shen","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.jmii.2017.04.001_bib23","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1365-3083.1991.tb01770.x","article-title":"Mechanism of T-cell activation by mycobacterial antigens in inflammatory synovitis","volume":"33","author":"Burford-Foggs","year":"1991","journal-title":"Scand J Immunol"},{"issue":"Suppl 3","key":"10.1016\/j.jmii.2017.04.001_bib24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/1756-185X.12539","article-title":"Risk of tuberculosis, serious infection and lymphoma with disease-modifying biologic drugs in rheumatoid arthritis patients in Taiwan","volume":"17","author":"Chiu","year":"2014","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.jmii.2017.04.001_bib25","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1164\/rccm.201305-0863OC","article-title":"Risk for tuberculosis in child contacts. Development and validation of a predictive score","volume":"189","author":"Chan","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jmii.2017.04.001_bib26","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1517\/14740338.2015.1009036","article-title":"Infection risk associated with anti-TNF-alpha agents: a review","volume":"14","author":"Murdaca","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jmii.2017.04.001_bib27","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1093\/rheumatology\/keq249a","article-title":"BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies","volume":"49","author":"Ding","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jmii.2017.04.001_bib28","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1183\/09031936.00028510","article-title":"The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement","volume":"36","author":"Solovic","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jmii.2017.04.001_bib29","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3109\/s10165-009-0243-4","article-title":"Minimal influence of tocilizumab on IFN-gamma synthesis by tuberculosis antigens","volume":"20","author":"Ogata","year":"2010","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.jmii.2017.04.001_bib30","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/rheumatology\/keq343","article-title":"Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials","volume":"50","author":"Campbell","year":"2011","journal-title":"Rheumatol Oxf"},{"key":"10.1016\/j.jmii.2017.04.001_bib31","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3109\/13506129.2011.613962","article-title":"Successful use of tocilizumab in a patient with nephrotic syndrome due to a rapidly progressing AA amyloidosis secondary to latent tuberculosis","volume":"18","author":"Magro-Checa","year":"2011","journal-title":"Amyloid"},{"key":"10.1016\/j.jmii.2017.04.001_bib32","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3109\/s10165-011-0488-6","article-title":"Incidence of serious respiratory infections in patients with rheumatoid arthritis treated with tocilizumab","volume":"22","author":"Hoshi","year":"2012","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.jmii.2017.04.001_bib33","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13075-015-0583-8","article-title":"Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry","volume":"17","author":"Sakai","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jmii.2017.04.001_bib34","first-page":"121","article-title":"Are glucocorticoids a consistent risk factor for infections in rheumatoid arthritis patients under treatment with methotrexate and etanercept?","volume":"160","author":"Luzi","year":"2009","journal-title":"Clin Ter"},{"key":"10.1016\/j.jmii.2017.04.001_bib35","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/imr.12249","article-title":"Cytokine and lipid mediator networks in tuberculosis","volume":"264","author":"Mayer-Barber","year":"2015","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jmii.2017.04.001_bib36","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.4049\/jimmunol.160.3.1290","article-title":"Cytokine activation leads to acidification and increases maturation of Mycobacterium avium-containing phagosomes in murine macrophages","volume":"160","author":"Schaible","year":"1998","journal-title":"J Immunol"},{"issue":"Suppl 1","key":"10.1016\/j.jmii.2017.04.001_bib37","first-page":"57","article-title":"Modulation of pro-inflammatory cytokine biology by unsaturated fatty acids","volume":"37","author":"Grimble","year":"1998","journal-title":"Z Ernahrungswiss"},{"key":"10.1016\/j.jmii.2017.04.001_bib38","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/infdis\/jit037","article-title":"Role of interleukin 6 in innate immunity to Mycobacterium tuberculosis infection","volume":"207","author":"Martinez","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jmii.2017.04.001_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0110922","article-title":"Rheumatoid arthritis increases the risk of nontuberculosis mycobacterial disease and active pulmonary tuberculosis","volume":"9","author":"Yeh","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jmii.2017.04.001_bib40","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.5588\/ijtld.13.0368","article-title":"Risk of tuberculosis in rheumatoid arthritis patients on tumour necrosis factor-alpha inhibitor treatment in Taiwan","volume":"17","author":"Ke","year":"2013","journal-title":"Int J Tuberc Lung Dis"}],"container-title":["Journal of Microbiology, Immunology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118217301044?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118217301044?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T13:23:15Z","timestamp":1761657795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1684118217301044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S1684118217301044"],"URL":"https:\/\/doi.org\/10.1016\/j.jmii.2017.04.001","relation":{},"ISSN":["1684-1182"],"issn-type":[{"value":"1684-1182","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of isoniazid salvage therapy for latent tuberculosis infection in patients with immune-mediated inflammatory disorders \u2013 A retrospective cohort study in Taiwan","name":"articletitle","label":"Article Title"},{"value":"Journal of Microbiology, Immunology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmii.2017.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}